Inogen (INGN) Stock
Portable oxygen concentrator maker for chronic respiratory patients. Here's the price, business snapshot, and what's worth knowing about Inogen in September 2026.
Inogen Inc (INGN) designs and sells portable oxygen concentrators used by people with chronic respiratory conditions such as COPD. Its products are aimed at providing mobility and home-based oxygen therapy through lighter, battery-powered devices sold via direct channels, home medical equipment providers and international distributors. Demand is supported by an ageing population and a shift from bulky oxygen tanks to portable solutions, but sales are sensitive to reimbursement policies, clinical adoption cycles and supply-chain dynamics. As a relatively small-cap medical-device company (market cap ~ $230m), Inogen may offer growth potential alongside greater volatility and execution risk than larger peers. Key factors to watch include product innovation, international expansion, service and accessory revenue, and regulatory oversight. This summary is general educational information only and not personal financial advice; values can fall as well as rise, so investors should consider their own risk tolerance and seek professional advice if needed.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Inogen's stock with a target price of $12, indicating significant growth potential.
Financial Health
Inogen is performing well with strong revenue and cash flow, although profit margins could improve.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Mobility trend
Portable oxygen devices support patient mobility and home care, a sector worth watching as ageing populations increase demand — though reimbursement shifts can affect uptake.
International expansion
Overseas markets and distributor networks offer growth opportunities, but local regulations and market access can create variability in outcomes.
Product innovation
Battery life, noise reduction and service offerings matter for competitiveness; technical advances may boost appeal, yet competition and execution risk remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
